Glumetza Direct Purchaser - Claim Management
If you purchased brand Glumetza® or generic Glumetza (Metformin HCl) between May 6, 2012 through August 15, 2020, a class action lawsuit could affect your rights.
Filing Deadline: TBA
Eligible Class Members: All persons or entities in the United States and its territories who directly purchased Glumetza or generic Glumetza from any of the defendants below.
“Defendants”: Bausch Health Companies Inc., Lupin Pharmaceuticals, Inc., Lupin Pharmaceuticals, Ltd., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Santarus, Inc., Depomed, Inc., and Assertio Therapeutics, Inc.
Claim Period: May 6, 2012 through August 15, 2020
Case History: Direct Purchaser Class Plaintiffs allege that Defendants violated federal antitrust laws by engaging in unlawful conduct to delay and impair competition of generic versions of the diabetes medication Glumetza® (metformin hydrochloride) extended release tablets (in both 500mg and 1000mg strengths). Direct Purchaser Class Plaintiffs allege that in February 2012, the defendants agreed in writing to delay the sale of the first generic competitor to Glumetza (by Defendant Lupin) until February 1, 2016 at the earliest and that in exchange, the Brand Defendants agreed to pay (and did pay) Defendant Lupin in the form of reimbursement of attorneys’ fees and an agreement to delay the launch of an authorized generic product. Direct Purchaser Class Plaintiffs allege that this payment included: (a) an agreement not to compete with Lupin’s generic with a Brand-authorized generic for twelve months, and (b) an agreement not to grant a license that would allow any other generic manufacturer to market a generic competitor to Lupin’s generic any earlier than August 1, 2016.
As alleged, the “pay for delay” scheme outlined by Direct Purchaser Class Plaintiffs allowed the Brand Defendants to greatly increase the price of Glumetza, protected Lupin from generic competition from the Brand and other generics, and made members of the Class pay more for brand or generic Glumetza. No court has determined whether Direct Purchaser Class Plaintiffs’ position or Defendants’ position is correct, and no trial has been held.
●Perform research to assure that all of your eligible business units (e.g., subsidiaries, divisions, acquisitions and divestitures) are included in the claim process.
●Provide advice on what, if any, documents need to be collected and maintained, and, when requested, we will assist in that effort.
●Reduce the support needed from your in-house staff, when required documents are not available or are too burdensome to collect, and we will negotiate on your behalf to develop alternate means to satisfy the documentation requirements.
●Provide regular updates on the recovery process and all related developments.
●Audit your payment to assure that it has not been under calculated.
●Follow up with you to assure that your recovery check is deposited.
●Notify you when we learn of additional valuable settlements in which you may be eligible to participate.
How to Retain FPS: To retain FPS to file and manage a claim on your behalf, we must receive a signed copy of our Service Agreement Authorization. Before you email or fax the executed Service Agreement Authorization it is important that you understand its terms and make sure that your basic information at the top of the page is correct.
Disclaimer: This is not an official Court Notice. Information contained in this Summary is subject to change. For additional settlement information, please contact Class Counsel or the Claims Administrator, or visit the court-approved website at https://glumetzaantitrustlitigation.com. Please understand that you have the right to file a claim on your own at no cost to you. © 2021. Financial Power Services, LLC